Patent Law Reforms Globally.
1. India – Section 3(d) Amendment (2005) and Novartis v. Union of India (2013)
Reform: India introduced Section 3(d) in its Patents Act to prevent “evergreening” of pharmaceutical patents. It restricts patents on minor modifications of existing drugs unless they show significant therapeutic efficacy.
Case: Novartis AG v. Union of India & Others (2013)
Facts: Novartis sought a patent for Glivec, a modified version of an existing cancer drug.
Issue: Whether the modification demonstrated enhanced therapeutic efficacy under Section 3(d).
Decision: The Supreme Court rejected the patent, holding that mere changes in formulation without significant efficacy are not patentable.
Significance: Established India as a global model for striking a balance between innovation and public health. Pharmaceutical companies must now demonstrate real therapeutic improvements for patent protection.
2. United States – America Invents Act (AIA, 2011)
Reform: Shifted the U.S. patent system from “first-to-invent” to first-to-file, streamlined post-grant opposition procedures, and introduced mechanisms to challenge weak patents.
Case: Oil States Energy Services v. Greene’s Energy Group (2018)
Facts: Oil States challenged patents through the newly created inter partes review (IPR) system under AIA.
Issue: Was the IPR process constitutional?
Decision: The U.S. Supreme Court upheld IPRs as valid administrative procedures.
Significance: Reforms strengthened patent quality control, allowing companies to challenge low-quality patents efficiently. This affected biotech, software, and pharma patents, especially where overlapping claims existed.
3. European Union – Unitary Patent and Unified Patent Court (UPC, 2023, ongoing)
Reform: The EU introduced the unitary patent system and the Unified Patent Court to streamline patent enforcement across multiple member states, reducing litigation complexity and costs.
Case: UPC Preparatory Case C-93/20
Facts: Dispute arose on how the UPC would handle cross-border infringement in multiple EU states.
Decision: The European Court of Justice clarified jurisdictional rules, emphasizing centralized enforcement and uniform validity review.
Significance: Simplifies patent litigation in regenerative medicine, pharma, and tech sectors, ensuring one court ruling applies EU-wide, reducing forum shopping.
4. China – Patent Law Amendments (2021)
Reform: China increased patent term compensation for delays, strengthened patent infringement damages, and streamlined examination procedures.
Case: Shenzhen Zhaopin Technology v. Huawei (2022)
Facts: Huawei sued for patent infringement; the dispute involved software and hardware integration patents.
Decision: Chinese courts awarded higher statutory damages under the reformed law, emphasizing deterrence against infringement.
Significance: Shows China’s commitment to strengthening IP enforcement, aligning with global innovation standards, particularly for technology and biotech sectors.
5. South Korea – Patent Act Amendments (2016–2020)
Reform: Introduced provisions to fast-track biotech, pharmaceutical, and regenerative medicine patents, reduced examination time, and enhanced patent linkage with regulatory approval.
Case: Samsung Biologics v. LG Chem (2019)
Facts: LG Chem alleged patent infringement in biopharmaceutical production.
Decision: Courts applied new fast-track examination rules and linkage provisions to confirm infringement and uphold patent rights efficiently.
Significance: Highlights how patent law reform can accelerate protection of high-tech biotech innovations, encouraging investment in R&D.
6. Brazil – Patentability of Pharmaceutical Products (2015–2017 Reforms)
Reform: Brazil clarified that patents for new uses of known compounds require proof of enhanced efficacy, aligning partly with India’s Section 3(d).
Case: Bayer v. Farmanguinhos (2016)
Facts: Bayer tried to patent a new drug formulation; public health agency Farmanguinhos contested based on lack of efficacy improvement.
Decision: Brazilian patent office rejected the patent; courts upheld the decision.
Significance: Reinforced public health priorities in patent law, limiting evergreening and improving access to medicines.
7. Japan – Amendments for Regenerative Medicine Patents (2014)
Reform: Introduced fast-track examination for regenerative medicine products, similar to the U.S. biotech priority review system.
Case: Kyoto University v. Japan Tobacco (iPSC patents, 2015)
Facts: Patent disputes over induced pluripotent stem cell (iPSC) generation methods.
Decision: Court upheld patents, emphasizing novelty and therapeutic application.
Significance: Showed Japan’s reforms incentivize regenerative medicine research, granting earlier protection to breakthrough biotech innovations.
Key Global Trends in Patent Law Reforms
Balancing Access and Innovation: India and Brazil limit evergreening; U.S., EU, and Japan prioritize fast-track protection for breakthroughs.
Centralized Enforcement: EU UPC simplifies cross-border litigation; China and South Korea increase damages to strengthen enforcement.
Tech-Specific Reforms: Many jurisdictions provide accelerated examination for biotech, regenerative medicine, and pharma.
Post-Grant Challenges: AIA in the U.S., opposition systems in EU/India allow quality control and prevent weak patents from blocking innovation.
Public Health Considerations: Patentability reforms increasingly consider social welfare and therapeutic efficacy, not just novelty.
RELATED Blog
comments